Holen Sie sich die Stockscreener-App
0.00
80.39%
-0.051
Schlusskurs vom Vortag:
$0.051
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$N/A
Einnahmen:
$13.53M
Nettoeinkommen (Verlust:
$-44.07M
KGV:
0.00
EPS:
-28.1869
Netto-Cashflow:
$-23.86M
1W Leistung:
-80.39%
1M Leistung:
-80.39%
6M Leistung:
-13.42%
1J Leistung:
-85.40%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$0.1956
Telesis Bio Inc Stock (TBIO) Company Profile
Firmenname
Telesis Bio Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare TBIO vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TBIO
Telesis Bio Inc
|
0.00 | 0 | 13.53M | -44.07M | -23.86M | -28.19 |
ABT
Abbott Laboratories
|
89.47 | 163.10B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
294.69 | 123.10B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
80.00 | 105.15B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
56.51 | 86.87B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.99 | 47.44B | 6.30B | 1.07B | 1.34B | 1.8406 |
Telesis Bio Inc Stock (TBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-03-18 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-03-18 | Herabstufung | Truist | Buy → Hold |
| 2020-10-05 | Eingeleitet | Goldman | Buy |
| 2020-07-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-06 | Eingeleitet | William Blair | Outperform |
| 2020-06-26 | Eingeleitet | SunTrust | Buy |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-06-18 | Eingeleitet | ROTH Capital | Buy |
| 2018-12-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-07-23 | Eingeleitet | Citigroup | Buy |
| 2018-07-23 | Eingeleitet | Evercore ISI | Outperform |
| 2018-07-23 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Telesis Bio Inc Aktie (TBIO) Neueste Nachrichten
Net current asset value per share of Telesis Bio, Inc. – OTC:TBIO - TradingView — Track All Markets
CapEx per share of Telesis Bio, Inc. – OTC:TBIO - TradingView — Track All Markets
Revenue per share of Telesis Bio, Inc. – OTC:TBIO - TradingView
EBITDA per share of Telesis Bio, Inc. – OTC:TBIO - TradingView
EBIT per share of Telesis Bio, Inc. – OTC:TBIO - TradingView
Cash per share of Telesis Bio, Inc. – OTC:TBIO - TradingView
J. Craig Venter launches genomics startup designed to boost diagnostic insights - Fierce Biotech
Statement of Changes in Beneficial Ownership (4) - ADVFN
Current Report Filing (8-k) - ADVFN
Small Company Offering and Sale of Securities Without Registration (d) - ADVFN
DNA Manufacturing Market Size to Hit USD 20.28 Billion by - GlobeNewswire
Enzymatic DNA Synthesis Market | Global Market Analysis Report2035 - Future Market Insights
WhiteFiber Shares Rise in Nasdaq Debut - MarketScreener
Telesis Bio(TBIO) Stock Options Chain | Quotes & News - Moomoo
Telesis Bio Inks Regeneron Deal - San Diego Business Journal
Telesis Bio and Regeneron Partner on Gene Synthesis - Technology Networks
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis - BioSpace
Driving Synthetic Biology Forward Through Adoption of Technology Enabling Rapid DNA and mRNA Synthesis - MedCity News
TBIO Stock Price, News & Analysis - Stock Titan
Telesis Bio Bullish on Future After Whirlwind Year - San Diego Business Journal
Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis - Business Wire
Nuclera appoints William J. Kullback as Non-Executive Director - Cambridge Network
From California to Cambridge: finance ace strengthens Nuclera board - Business Weekly
Carver Bancorp Leads 3 Noteworthy US Penny Stocks - simplywall.st
Telesis Bio secures $3 million in promissory notes By Investing.com - Investing.com UK
Telesis Bio Inc. (TBIO) Quarterly 10-Q Report - qz.com
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket - TradingView — Track All Markets
Telesis Bio Stock Is Soaring Wednesday: What's Going On? - TradingView — Track All Markets
Is Telesis Bio Inc. on the Brink of a Major Breakthrough? - timothysykes.com
Telesis Bio Inc. (NASDAQ: TBIO)Share Price - intelligentinvestor.com.au
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.31% - Investing.com UK
Telesis Bio to delist from Nasdaq by end of September - Investing.com
Telesis Bio reshuffles board, appoints new chairs By Investing.com - Investing.com Australia
Telesis Bio completes sale of subsidiary EtonBio - Investing.com
Yuan Yang completed the acquisition of Eton Bioscience, Inc. from Telesis Bio, Inc. - marketscreener.com
DNA Synthesis Market Size, Share | Growth Report [2034] - Fortune Business Insights
Automating DNA Synthesis Boosts Drug Discovery: - Mary Ann Liebert, Inc.
Telesis Bio announces reverse stock split By Investing.com - Investing.com Nigeria
Telesis Bio appoints new CEO as founder steps down - Investing.com
Telesis Bio: Q4 Earnings Snapshot - qz.com
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results - Macau Business
Pre-market Movers: HSCS, RNA, THAR, BGLC... - RTTNews
Telesis Bio: Q3 Earnings Snapshot - qz.com
About Us - FinancialContent
Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA - FinancialContent
Laser Focus WorldTelesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS - FinancialContent
New research finds that despite the stereotypes, women actually negotiate their salaries more than men - Fortune
Eric Eugene Esser Net Worth (2026) - GuruFocus
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit - Technology Networks
Sidley Represents Northpond Ventures in Its PIPE Investment in Telesis Bio Inc. - Sidley Austin
Telesis Bio Captures $28M in Financing, $46.2M Available With Warrant Exercise - SynBioBeta
Finanzdaten der Telesis Bio Inc-Aktie (TBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
0.86%
Kapitalisierung:
|
Volumen (24h):